All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Skyhawk, Merck enter $2bn collaboration for RNA-targeting therapies
The partnership, valued at over $2bn, aims to advance RNA modulation in diseases where conventional methods have faced hurdles.
CSL to spin off vaccine division, reduce 15% workforce
The restructuring may affect up to 3,000 employees, enhancing its clinical and commercial operations and streamlining costs and decision-making processes.
Tonix receives FDA approval for Tonmya in fibromyalgia
Tonmya is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride that offers rapid transmucosal absorption and reduced production of norcyclobenzaprine.
Novo Nordisk secures FDA approval for Wegovy to treat MASH
Wegovy is approved for use alongside a reduced-calorie diet and increased physical activity to treat MASH in adults with liver fibrosis.
Keytruda approved in Canada for advanced head and neck cancer
Keytruda is indicated for adult patients with resectable locally advanced head and neck squamous cell carcinoma, expressing PD-L1.
Apertura signs licensing agreements with Galibra and Emugen
Galibra and Emugen will use Apertura’s advanced transferrin receptor 1 capsid for their central nervous system treatments.
AbbVie to invest $195m in new API production facility in US
The expansion will bolster AbbVie’s domestic API production, supporting advancements in neuroscience, immunology, and oncology medicines.
Insmed secures FDA approval for Brinsupri to treat NCFB
Brinsupri is a DPP1-inhibitor, indicated for the treatment of adults and children with NCFB, aged 12 years and above.
Novartis’ Phase 3 trials of ianalumab meet primary endpoints
The primary endpoints of both trials were measured by improvements in disease activity using the ESSDAI, compared to a placebo.
Fosun Pharma, Expedition enter $645m licensing deal for XH-S004
The agreement provides Expedition with rights outside Chinese Mainland, Hong Kong SAR, and Macau SAR, while Fosun retains rights within these regions.